Qualitative & Semi-Quantitative Insight from Key Opinion Leaders on Mirikizumab in Moderate-to-Severe UC, 2018 Study

Dublin, Feb. 22, 2019 (GLOBE NEWSWIRE) -- The "KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC" drug pipelines has been added to ResearchAndMarkets.com's offering.

This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.

Questions topics

• Perception of Phase II mirikizumab induction data in UC
• Perception of mirikizumab's Phase III study in UC
• Future expectations of mirikizumab in UC
• Future expectations for mirikizumab in Crohn's disease

Key Highlights

• All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response
• Endoscopic & histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab's ongoing Phase III UC trial
• KOLs could not differentiate the clinical profile of mirikizumab in UC from other anti-IL-23s, and were divided over its dosing regimen.

Scope

• The insight briefing is based on Sociable Pharma's analysis of primary research with our ulcerative colitis key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs

• 5 Europe-based & 5 N. America-based
• Interviews performed during July 2018

KOL data is analyzed to produce

• Charts summarizing KOL opinions
• Chart call-outs of key information & details
• KOL quotes
• Summary of KOL reporting trends
• Insight from Sociable Pharma's analysts

Reasons to Buy

• Combines Qualitative & semi-quantitative insight from key opinion leaders on mirikizumab in moderate-to-severe UC
• Includes insight & recommendations from our disease-specific healthcare analysts
• Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC
• Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Key Topics Covered:

1. Executive Summary
2. Background
3. Research Panel Composition
4. Results & Implications
5. Appendix

Companies Mentioned

• Lilly
• Takeda
• Pfizer
• Janssen

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cj9csp/qualitative_and?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Gastrointestinal Drugs